The enhanced intracellular survival (Eis) protein of () is a versatile acetyltransferase that multiacetylates aminoglycoside antibiotics abolishing their binding to the bacterial ribosome. When overexpressed as a result of promoter mutations, Eis causes drug resistance. In an attempt to overcome the Eis-mediated kanamycin resistance of , we designed and optimized structurally unique thieno[2,3-]pyrimidine Eis inhibitors toward effective kanamycin adjuvant combination therapy. We obtained 12 crystal structures of enzyme-inhibitor complexes, which guided our rational structure-based design of 72 thieno[2,3-]pyrimidine analogues divided into three families. We evaluated the potency of these inhibitors as well as their ability to restore the activity of kanamycin in a resistant strain of , in which Eis was upregulated. Furthermore, we evaluated the metabolic stability of 11 compounds . This study showcases how structural information can guide Eis inhibitor design.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385556PMC
http://dx.doi.org/10.1021/acschembio.0c00184DOI Listing

Publication Analysis

Top Keywords

eis
6
structure-guided optimization
4
optimization inhibitors
4
inhibitors acetyltransferase
4
acetyltransferase eis
4
eis enhanced
4
enhanced intracellular
4
intracellular survival
4
survival eis
4
eis protein
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!